We focus on chronic and progressive inflammatory diseases with a high unmet need for targeted therapies
Dysregulated inflammation is central to many serious diseases and current treatment paradigms are inadequate to stop disease progression. We see a significant opportunity to serve patients and the overall marketplace with our highly differentiated and locally acting therapies across a wide range of inflammatory diseases.
First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation
ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2-mediated neutrophil trafficking into and FPR1-mediated neutrophil activation within the colonic lumen. Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study and MAD patient study, ADS051 was safe and well tolerated and restricted to the gut with limited systemic exposure.
Portfolio of First-In-Class Small Molecule Inhibitors of the NLRP3 and 1 Inflammasomes
ADS032 is a novel small molecule inhibitor that blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases. Our development candidates are focused on Respiratory and Dermal inflammation.